0000000000843589

AUTHOR

Véronique Lorgis

showing 3 related works from this author

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unk…

2021

Abstract Background Poorly differentiated neuroendocrine carcinomas (NEC) are rare diseases with a poor prognosis. Platinum-etoposide (PE) has been the recommended first-line treatment for decades. FOLFIRINEC (NCT04325425) is a national multicenter randomized phase II study which aims to challenge this standard regimen. Methods The primary objective is to compare the median progression-free survival (PFS) under mFOLFIRINOX versus PE. The secondary objectives are to evaluate the objective response rates (ORR), median overall survival (OS), safety and quality of life. The associated real-time translational study will establish a molecular profile for each patient enrolled. Main inclusion crit…

OncologyMaleFOLFIRINOXmedicine.medical_treatmentLeucovorinPhases of clinical researchPlatinum Compounds0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesNeoplasm MetastasisEtoposideEtoposideGastroenterologyEvaluable DiseaseProgression-Free Survival3. Good healthFOLFIRINOXOxaliplatinSurvival RateNeuroendocrine TumorsTreatment Outcome030220 oncology & carcinogenesisNeuroendocrine carcinoma030211 gastroenterology & hepatologyFemaleFluorouracilmedicine.drugAdultmedicine.medical_specialtyIrinotecanGastroenteropancreatic03 medical and health sciencesStomach NeoplasmsInternal medicineIntestinal NeoplasmsmedicineChemotherapyHumansContraindicationChemotherapyHepatologyPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyCarcinoma NeuroendocrinePancreatic NeoplasmsRegimenQuality of LifeNeoplasms Unknown PrimarybusinessBiomarkersDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treat…

2020

Background Cancer patients are thought to have an increased risk of developing severe Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, predictive factors for COVID-19 severity and mortality in cancer patients were investigated. Patients and Methods In this large nationwide retro-prospective cohort study, we collected data on patients with solid tumours and COVID-19 diagnosed between March 1 and June 11, 2020. The primary endpoint was all-cause mortality and COVID-19 severity, defined as admission to an intensive care unit (ICU) and/or mechanical ventilation and/or death, was one of the secondary endpoints. Results From April 4 to June 11, 2020, 1289…

Male0301 basic medicineCancer Researchmedicine.medical_treatmentDiseaselaw.inventionCohort Studies0302 clinical medicineMechanical ventilationRisk FactorslawNeoplasmsMedicineProspective StudiesProspective cohort studyOriginal ResearchCancerIntensive care unit3. Good healthDeathOncology030220 oncology & carcinogenesisFemaleFranceImmunotherapyCohort studymedicine.medical_specialtychemotherapy. radiotherapyAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInternal medicineHumansChemotherapyIntensive care unitMortalityPandemicsAgedRetrospective StudiesChemotherapyRadiotherapySARS-CoV-2business.industryCancerCOVID-19Retrospective cohort studyOdds ratiomedicine.diseaseAged; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; COVID-19/mortality; Cohort Studies; Female; France/epidemiology; Humans; Male; Neoplasms/mortality; Neoplasms/therapy; Neoplasms/virology; Pandemics; Prospective Studies; Retrospective Studies; Risk Factors; SARS-CoV-2/isolation & purification; COVID-19; Cancer; Chemotherapy; Death; Immunotherapy; Intensive care unit; Mechanical ventilation; Mortality; Radiotherapy030104 developmental biologybusiness
researchProduct

Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

2015

Abstract Purpose: To investigate the value of the metabolic tumor response assessed with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), compared with clinicobiologic markers to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in women with triple-negative breast cancer (TNBC). Experimental Design: Fifty consecutive women with TNBC and an indication for NAC were prospectively included. Different pretreatment clinical, biologic, and pathologic biomarkers, including SBR grade, the Ki-67 proliferation index, androgen receptor expression, EGF receptor (EGFR), and cytokeratin 5/6 staining, were assessed. Tumor glucose metabolism at baseline and its chan…

OncologyAdultCancer Researchmedicine.medical_specialtyPathologyProliferation indexmedicine.medical_treatmentBiopsyTriple Negative Breast NeoplasmsBreast cancerFluorodeoxyglucose F18Internal medicineBiopsyAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansEpidermal growth factor receptorTriple-negative breast cancerNeoadjuvant therapyAgedNeoplasm StagingChemotherapymedicine.diagnostic_testbiologybusiness.industryOdds ratioMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyNeoadjuvant TherapyTumor BurdenGlucoseTreatment OutcomeOncologyROC CurveLymphatic MetastasisPositron-Emission Tomographybiology.proteinFemaleNeoplasm GradingbusinessTomography X-Ray ComputedBiomarkersClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct